Fellowship · Aurora, CO
Sponsored by University of Colorado School of Medicine
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
American journal of respiratory and critical care medicine · 2022 · 341 citations · Scott Sagel
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
American journal of respiratory and critical care medicine · 2021 · 251 citations · Edith Zemanick
Embracing the challenges of neonatal and paediatric pulmonary hypertension.
The European respiratory journal · 2024 · 80 citations · Steven Abman
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
American journal of respiratory and critical care medicine · 2023 · 128 citations · Jordana Hoppe
Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection.
Cell · 2022 · 202 citations · Stacey Martiniano
The Lancet Child & Adolescent Health Commission on the future of neonatology.
The Lancet. Child & adolescent health · 2025 · 47 citations · Steven Abman
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023 · 103 citations · Scott Sagel
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
The Lancet. Respiratory medicine · 2025 · 44 citations · Jordana Hoppe